Organisations or companies exploiting blood-derived medicinal products which have knowledge of adverse reactions likely to be due to these medicinal products inform the Director General of the Agence nationale de sécurité du médicament et des produits de santé under the conditions set out in articles R. 5121-171 to R. 5121-173.